1.The changes and significance of inflammatory cell count in the induced sputum from children with different periods of asthma
Chinese Journal of Primary Medicine and Pharmacy 2015;22(2):200-202
Objective To study the different periods of childhood bronchial asthma induced sputum of the percentage change of inflammatory cells,and to explore part of the pathogenesis of asthma in children.Methods 69 children with asthma(the age ≥5 years old) were selected.By clinical symptoms,they were divided into acute exacerbation and clinical remission of 3 months and 6 months.At the same time,in the same groups of hospital pediatric clinic,22 healthy children were chosen as control group.The percentage of neutrophils and eosinophils in induced sputum was detected.Through the comparison,we can explore the correlation between the two kinds of inflammatory cells in different periods of asthma.Results Comparing the percentage of neutrophils among the four groups,acute exacerbation group was compared with clinical remission three months group,clinical remission six months group and the normal control group,acute exacerbation group was higher than the clinical remission group of three months,clinical remission of six months and normal control group [(57.905 ± 11.615)% vs (40.137 ± 11.668)%,(33.825 ± 12.457) %,(23.836 ± 13.585) %,P =0.039,0.000,0.000].The clinical remission of three months and clinical remission six months group were higher than the normal control group(P =0.000,0.032).The clinical remission of three months group and 6 months group had no significant difference (P =0.538).The percentage of eosinophils in acute exacerbation group was higher than the clinical remission of three months group,clinical remission of six months and normal control group [(4.090 ± 1.452) % vs (2.685 ± 1.190) %,(2.151 ± 1.417) %,(1.848 t 0.887) %,P =0.002,0.000,0.000].The clinical remission of three months group and the normal control group had no significant difference (P =0.937).Conclusion Asthma in children induced sputum neutrophil percentage and eosinophil percentage are significantly higher in acute exacerbation.The study shows that neutrophils and eosinophils are involved in the part of the pathogenesis of bronchial asthma in children.
2.Discussion on Development of Drug Data Protection in China
China Pharmacy 2005;0(21):-
OBJECTIVE: To discuss the development of drug data protection in China. METHODS: The specific data protection measures taken by United States (US) and the European Union (EU) were compared and the drawbacks of China drug data protection were analyzed; then some suggestions were put forward. RESULTS & CONCLUSION: The drug data protection in China is still only in its infancy. The Chinese government and drug administration should work out definite drug data protection bylaws by drawing experiences from US and EU.
3.Determination of Chrysophanol in Jiangzhiling Capsules by HPLC
Xiaomeng ZHANG ; Zhiyuan JIANG
Traditional Chinese Drug Research & Clinical Pharmacology 2000;0(05):-
Objective To establish a method for the determination of Chrysophanol in Jiangzhiling Capsules. Methods RP-HPLC was used for samples separating on a Nova-Pak C18 column. The mobile phase consisted of methanol-0.1 %H3PO4(85 ∶15). The detection wavelength was 254 nm and the flow rate was 1 mL?min-1.Results The standard curve of Jiangzhiling Capsules was linear in the rang of 0.037 5~0.750 0 ?g (r=0.999 9) with average recovery of 98.31 %(RSD=1.36 %). Conclusion The method is simple,accurate and precise. It can be used effectively for the quality control of Jiangzhiling Capsules.
4.Effects of Carvedilol on Blood Pressure in Hypertensive Patients and Vascular Endothelial Function
Jianhui WEI ; Xuebin LI ; Xiaomeng ZHANG
China Pharmacy 2007;0(32):-
OBJECTIVE: To investigate the effects of carvedilol on blood pressure in hypertension patients and vascular endothelial function. METHODS: 100 inpatients with primary hypertension were collected from our hospital from Jan. 2008 to Jan. 2010 and randomly divided into treatment group and control group(n=50). Treatment group were given initial oral dose of carvedilol tablets 6.25 mg twice a day for 7~14 days if it was tolerated; the dose of carvedilol tablets increased to 12.5 mg or 25 mg twice a day according to blood pressure at trough concentration if it was necessary. Control group were given carvedilol tablets 6.25 mg twice a day if it was tolerated. After 1 week, control group received double dose of metoprolol with maximum dose of carvedilol of 50 mg. The treatment course was 3 months. The contents of NO and ET in serum of 2 groups were detected. Antihypertensive effect and effects of carvedilol on vascular endothelial dilatation and systolic function were observed and compared between 2 groups. RESULTS: After treatment, the systolic and diastolic blood pressure in both groups were decreased significantly(P
5.The influence of mass screening for prostate cancer on the diagnostic status of the clinical prostate cancer
Ling ZHANG ; Guoyi JI ; Xiaomeng LI
Chinese Journal of Urology 1994;0(02):-
Objective To investigate the influence of t he mass screening on the diagnostic status of the conventional ordinary prostati c cancer (CaP). Methods Sixty seven cases of prostate ca ncer detected by mass screening (January 1996~December 2001) and 358 cases diag n osed at the outpatient of various hospitals in Changchun (January 1986~December 2001) were compared in terms of age distribution,clinical stages,level of serum prostate special antigen(PSA),pathological grade and treatment modalities,with a SPSS analysis system. Results The annual average incide nce of CaP during 1999 to 2001 increased 4.72 times when compared to the 1986 to 1989’s.In the screening group,the cases with clinical stage A and B accounted for 58.2%. In the clinical group, it was only 27.9%,and mostly detected incident ally.Furthermore,in the screening group the percentage of the cases beyond 20 ng /ml PSA and of poorly differentiated carcinoma were much lower compared to the c linical group.These differences were statistically significant.The cases of radi cal prostatectomy in the screening group increased 15.3% compared with that of t he clinical group. Conclusions Only the mass screening c an really reveal the actual prevalence of prostate cancer.It can markedly raise the number of prostate cancer,especially the cancer in the early stage.The mass screening is inevitable to detect the curable early stage prostate cancer.
7.Clinical Effect of Neoadjuvant Chemotherapy Combined with PA-MSHA Injection on Breast Cancer
Oixin MAO ; Min ZHANG ; Xiaomeng HAO ; Sheng ZHANG ; Jin ZHANG
Chinese Journal of Clinical Oncology 2010;37(2):117-120
Objective: To evaluate the effect and safety of neoadjuvant chemotherapy combined with PA-MSHA injection for breast cancer patients. Methods: An open randomized controlled clinical trial was con-ducted. Fourty patients with breast cancer were randomly assigned to neoadjuvant chemotherapy group (the control group, n=20) and neoadjuvant chemotherapy combined with PA-MSHA injection group (the experi-ment group, n=20). The evaluation of therapeutic effect was carried out when the treatment was completed. Kamofsky score was recorded before and after therapy. Venous blood was drawn before and after therapy and immune function (IFN-γ, IL-2, IL-4, and IL-10) and other indicators (Caspase-3, VEGF, MMP-2 and MMP-9) were measured by double antibody ELISA test. Adverse effects of PA-MSHA during therapy were ob-served and recorded. Results: The overall response rate (RR) in the experiment group was significantly higher than that in the control group (P<0.05). No significant difference was found in the pathologic complete remis-sion (pCR) between the experiment group and the control group (P>0.05). In the experimental group, pCR was significantly different before and after therapy (P<0.01). The score in the experimental group was signifi-cantly higher than that in the control group after therapy (P<0.01). With the treatment of chemotherapy and PA-MSHA injection, IFN-γ and IL-2 levels were significantly higher while IL-4 and IL-10 levels were significant-ly lower in the experiment group (P<0.05). A significant increase in serum Caspase-3 and a significant de-crease in serum VEGF, MMP-2 and MMP-9 (P<0.05) after therapy were also observed in the experimental group. The level of serum MMP-9 was decreased significantly (P=<0.05) after therapy in the control group. Con-clusion: Neoadjuvant chemotherapy combined with PA-MSHA injection can significantly improve the RR of breast cancer patients, enhance their cellular immune function, induce the apoptosis and restrain the metasta-sis of breast cancer cells. The PA-MSHA has been proved to be an ideal supplementary therapy for breast cancer.
8.Operation pathways for sphenoidal sinus by nasal endoscope and treatments for correlated diseases beyond scope of sphenoidal sinus
Jianxin YUE ; Weijia KONG ; Song ZHANG ; Yanjun WANG ; Xiaomeng ZHANG
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2009;(20):920-922
Objective:We probe more direct operation pathways in sphenoidal sinus and saddle area, and take proper measures for correlated diseases which surpass scope of sphenoidal sinus by combining image data, which could prevent serious complication.Method:Under nasal endoscope, the operation approaches we adopted included trans-anterior ethmoid sinus-posterior ethmoid sinus-sphenoidal sinus pathway, trans-meatus nasi superior-posterior ethmoid sinus-sphenoidal sinus pathway, trans nasal septum-sphenoidal sinus pathway and trans-natural opening of sphenoid sinus anterior into sphenoid sinus pathway by taking upper edge of posterior naris as a consistent surgical landmark. Forty-six cases who had sphenoidal sinus mass with bone erosion recieved surgical treatment.Result:Twenty-one cases with cyst and pus cyst of sphenoidal sinus had been healed by trans-meatus nasi superior pathway;1 case with hematoma and organization in sphenoidal sinus had been cleared by trans-meatus nasi superior pathway;3 cases had hematoma and organization in sphenoidal sinus and pseudoaneurysm in internal carotid artery,one of them suffered fatal hemorrhage in surgical exploration, and cured by endovascular embolization, the other two only underwent nasal endoscopic examination,the diagnosis was established by DSA and they received interventional therapy;4 cases with papilloma in sphenoidal sinus had been treated by trans-natural opening of sphenoid sinus approach,and 3 cases were cured,1 case had only partial mass resection as the papilloma offended the outer wall of sphenoidal sinus diffusely;2 cases with cholesteatoma of sphenoid sinus have been removed completely by trans-meatus nasi superior approach;1 case with encephalomeningocele of sphenoidal sinus underwent sphenoidotomy by trans-natural opening of anterior of sphenoidal sinus, and intraoperative puncture showed characteristic cerebrospinal fluid,the exposed meninges were then repaird surgically;1 case with mycosis of sphenoidal sinus had been cured by thorough clearing of the leision in sphenoidal sinus combined with antifungal therapy;3 cases with malignancy of sphenoidal sinus had received major mass resection of sphenoidal sinus by trans-anterior ethmoid sinus-posterior ethmoid sinus approach, and followed with radio therapy and chemotheraphy;5 cases with NPC in-volving sphenoidal sinus had been treated by radio therapy and chemotherapy after pathological examinacation;5 cases with post-operative cerebrospinal rhinorrhea and granulation hyperplasia of sphenoidal sinus had been repaired successfully by trans-meatus nasi superior approach or tans-nasal septum approach.Conclusion:There are various surgical pathways to deal with sphenoidal sinus and correlated diseases under nasal endoscope.The operation will be direct, safe and minimal invasive if we choose the pathway properly. Thin slice CT scan and 3D reconstruction of sella, and DSA or angiography of brain before operation is one of effective means to prevent surgical complications for leisions beyond scope of sphenoidal sinus.
9.Rules of Property of Drugs Used by State Medical Master Yan Zhenghua Based on Data Mining
Jiarui WU ; Weixian GUO ; Xiaomeng ZHANG ; Bing ZHANG
Chinese Journal of Information on Traditional Chinese Medicine 2014;(8):16-18
Objective To analyze the rules of property of the drugs used by State Medical Master Yan Zhenghua in clinical.Methods The prescriptions used by Pro. Yan were collected to build a database, which was based on traditional Chinese medicine inheritance assistant software. After analyzed by the software, such as using the module to analyze the prescriptions, the medication characters of the prescriptions can be got from the database.Results Drugs of warm nature were used with the highest frequency 7998 times, followed by the cool 7866 times, leveling 6763 times, cold 3942 times, and hot 95 times. From the property of five flavors, the most used flavor of drugs was bitter 15260 times, followed by sweet 10810 times, pungent 10453 times, sour 2794 times, salty 1651 times, mild 1203 times, and astringency 186 times. In the frequency of the channel tropism involved, the highest is of liver channel 14237 times, followed by lung 10452 times and spleen 10061 times.Conclusion Pro. Yan was accustomed to using the drugs that were of warm and cool natures, and sweet and pungent flavors, and also the drugs that have action on the collateral channels of liver, lung and spleen, which were the same as the experience from Pro. Yan.
10.Clinicopathologic characteristics and prognostic analysis of luminal B breast cancer patients with diabetes
Bei SUN ; Guofang HOU ; Xiaobei ZHANG ; Xiaomeng HAO ; Sheng ZHANG
Chinese Journal of Clinical Oncology 2013;(17):1042-1046
Objective:To investigate the clinical, pathological, and prognostic characteristics of luminal B breast cancer patients with diabetes. Methods:A total of 479 luminal B breast cancer patients with diabetes and 3 392 luminal B breast cancer patients without diabetes who were treated between January 2002 and December 2006 were enrolled in this study. The luminal B breast cancer patients were further divided into the luminal B (high ki67) and luminal B (Her-2/neu+) subgroups. Each subgroup was further grouped into metformin-treated, non-metformin-treated, and non-diabetic groups. The indicators included cancer-specific mortality, clinical, pathological stage, lymph node status, chemotherapy, and endocrine therapy. The survival analysis of each group was performed using the Kaplan-Meier method, and the significance was determined using the logrank test. Cox proportional hazard model was used to examine the correlation between each factor and the prognosis. Results:The Kaplan-Meier analysis results revealed that the breast cancer mortality rates in the metformin-treated, non-metformin-treated, and non-diabetic groups were significantly different in both luminal B (high ki67) and luminal B (Her-2/neu+) subgroups (logrank test:P<0.001, P=0.035), and the respective five-year survival rates were 93.5%, 81%, and 89%for the luminal B (high ki67) subgroup and 84%, 77%, and 83%for the luminal B (Her-2/neu+) subgroup. The Cox multifactorial regression analysis results showed that compared with the metformin-treated group, the non-metformin-treated group was associated with a significantly increased risk of mortality (P<0.001, P=0.044) in the two subgroups. Meanwhile, the non-diabetic group was associated with an increased risk of mortality (P=0.038) in the luminal B (high ki67) subgroup only. The percentage of elderly (P<0.001), menopausal (P<0.001), obese (P<0.001), and patients with cardio-cerebrovascular complications (P<0.001) tended to be higher in the metformin-treated and non-metformin-treated groups than in the diabetic group. Moreover, the metformin-and non-metformin-treated groups in the luminal B (high ki67) subgroup were associated with high percentages of T3/4 pathological stage (P<0.001), lymph node metastasis (P=0.001). The non-metformin-treated group was associated with a lower percentage of invasive ductal carcinoma (P=0.001) compared with the other two groups. Conclusion:The non-metformin-treated group resulted in worse clinical outcomes in both subgroups compared with the metformin-treated group. Meanwhile, the non-diabetic group resulted in the worst prognosis among the three groups in the luminal B (high ki67) subgroup. These findings suggest that the choice of different anti-diabetic drugs may influence the prognosis of luminal B breast cancer patients with diabetes.